Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients

Next Previous
X
Search
Trial Profile

A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vismodegib (Primary) ; Antineoplastics
  • Indications Basal cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RegiSONIC
  • Sponsors Genentech

    • Most Recent Events

    • 25 Jul 2017 Status changed from active, no longer recruiting to discontinued.
    • 08 Mar 2016 Results of a preliminary sub-group analysis (n=88) presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 20 May 2015 According to Curis media release, data from this and other two trials ( see profile 209178 and 200209) will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top